Fentanyl has become a crisis in the United States of America. And now, there’s a new biotech startup aiming to solve it.

What’s happening:

  • ARMR Sciences is raising $30M USD in a new financing round to accelerate the development of their novel immunotherapy drug focused on providing protection to fentanyl and synthetic opioids

Why it matters:‍

  • ARMR Sciences flagship drug ARMR-100 is aiming to be the first ever drug that could be taken in advance of potential exposure to fentanyl and prevent fentanyl from reaching the human brain

Going deeper:‍

  • ARMR-100 was developed at the University of Houston and has shown clinical validation in initial animal studies that have been conducted
  • Psychedelic drug developer MindMed (NASDAQ: MNMD) co-founder JR Rahn is one of the co-founders of ARMR Sciences

The intrigue:‍

  • ARMR Sciences has also publicly stated they plan to list onto the Nasdaq imminently following the completion of their capital raise